Statin therapy for healthy men identified as "increased risk"

JAMA

Volumn 307, Issue 14, 2012, Pages 1489-1490

  Blaha, Michael J ^a   Nasir, Khurram ^a   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; ETHNICITY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LONG TERM CARE; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84859552802     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.425     Document Type: Short Survey

References (10)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239. (Pubitemid 38924592)
2. Shepherd J, Cobbe SM, Ford I, et al West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301-1307.
3. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622.
4. Ridker PM, Danielson E, Fonseca FA, et al JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
5. Ridker PM, Macfadyen JG, Nordestgaard BG, et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Circ Cardiovasc Qual Outcomes. 2010; 3(5):447-452.
6. Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events. Lancet. 2011;378 (9792):684-692.
7. Bernick C, Katz R, Smith NL, et al Cardiovascular Health Study Collaborative Research Group. Statins and cognitive function in the elderly. Neurology. 2005; 65(9):1388-1394.
8. Lytsy P, Burell G, Westerling R. Cardiovascular risk factor assessments and health behaviours in patients using statins compared to a non-treated population [published online April 15, 2011]. Int J Behav Med. doi:10.1007/s12529-011-9157-6.
9. Kostis WJ, Moreyra AE, Cheng JQ, Dobrzynski JM, Kostis JB. Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy. J Clin Lipidol. 2011;5(2):97-104.
10. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59(6):572-582.